A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials

Table 1 Descriptive characteristics of survey respondents (n = 18)

Organisation type and number of ongoing clinical trials prior to COVID-19	Organisation’s usual role in clinical trials	Reply on behalf of	Geographical location
CRO (n = 2)
≥ 100	CRO	Organisation	USA/Europe
10 to < 100	CRO, SMO	Organisation	Europe
Pharmaceutical company (n = 9)
≥ 100	Industry sponsor	Organisation	Europe/UK
	Industry sponsor	Organisation	Others
	Industry sponsor	Organisation	USA
	Industry sponsor	Organisation	Europe
10 to < 100	Industry sponsor	Organisation	Europe
	Industry sponsor	Unit/department	USA/Europe
	Industry sponsor	Organisation	Others
	Industry sponsor	Organisation	Europe
Unknown	Industry sponsor	Organisation	Europe
Research Network (n = 2)
10 to < 100	Technology provider	Unit/department	Europe
< 10	Site	Unit/department	Europe
Technology company (n = 3)
10 to < 100	Technology provider	Organisation	UK
10 to < 100	Technology provider	Unit/department	Europe
< 10	Technology provider	Unknown	Europe
University (n = 2)
< 10	Clinical Trial Unit	Unit/department	Europe
< 10	Clinical Trial Unit	Unit/department	UK

ISSN: 1745-6215